We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HWH:NASDAQHWH International Inc. Analysis

Data as of 2026-06-13 - not real-time

$1.77

Latest Price

8/10Risk

Risk Level: High

Executive Summary

HWH International Inc. is trading at $1.77, comfortably above its 20‑day ($1.17) and 50‑day ($1.11) simple moving averages and showing a bullish MACD crossover, yet the RSI of 79 signals an overbought condition. Volatility is extreme at over 100% (30‑day) and the stock has suffered a historic max drawdown of 85%, underscoring a high risk profile. Fundamentally, the company reports a 78% revenue decline, negative operating margins (‑9.7%) and a DCF‑derived fair value of just $0.33, indicating the market price is significantly overvalued. Insider activity – a majority shareholder increased its stake to 80.5% and purchased 250,000 shares at $2.00 – drove a sharp after‑hours rally, but this capital infusion has not yet translated into improved cash‑flow or earnings.
Given the disconnect between lofty valuation multiples (P/B 6.6, P/S 20.8) and weak financials, coupled with high price volatility and limited liquidity, the stock appears speculative. Investors should weigh the potential upside from insider confidence against the substantial downside risk reflected in the technical overbought signal and deteriorating fundamentals.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Overbought RSI indicating near‑term pullback
  • Extreme price volatility and recent max drawdown
  • Technical resistance near $2.60

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Insider capital injection may support operational turnaround
  • Persistent negative margins and weak cash‑flow
  • Valuation still far above DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fundamentals remain deteriorated with steep revenue decline
  • High debt‑to‑equity ratio relative to a micro‑cap company
  • Sustained overvaluation versus book and sales multiples

Key Metrics & Analysis

Financial Health

Revenue Growth-78.30%
ROE-93.89%
ROA-37.01%
Debt/Equity38.75
P/B Ratio6.6
Op. Cash Flow$-1387496
Free Cash Flow$129.9K

Technical Analysis

TrendNeutral
RSI78.9
Support$1.00
Resistance$2.60
MA 20$1.17
MA 50$1.11
MA 200$1.77
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$0.33
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.14
Volatility100.63%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.